Sotera Health Co
Close on Oct 19, 2026
- Market cap
- $5.08B
- P/E (TTM)
- 30.9
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $321.38M | $0.19 | $0.26 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $280.05M | $0.09 | $0.18 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $311.00M | $0.17 | $0.26 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | $294.00M | $0.03 | $0.20 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $255.00M | $-0.05 | $0.14 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $290.00M | $0.04 | $0.21 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $285.00M | $0.06 | $0.17 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | Full-Year 2026 | $200.00M to $225.00M | Raised |
| Adjusted EBITDA constant currency growthnon-GAAP | Full-Year 2026 | 5.75% to 7.25% growth | New |
| Adjusted EBITDAnon-GAAP | Full-Year 2026 | $634.00M to $643.00M | Raised |
| Adjusted EPSnon-GAAP | Full-Year 2026 | $0.95 to $1.01 | Raised |
| weighted-average fully diluted share count | Full-Year 2026 | 289 to 291 | Maintained |
| Tax rate applicable to Adjusted Net Incomenon-GAAP | Full-Year 2026 | 27% to 28% | Lowered |
| Interest expense | Full-Year 2026 | $135.00M to $142.00M | Lowered |
| constant currency growthnon-GAAP | Full-Year 2026 | 5.25% to 6.75% growth | New |
| Net revenues | Full-Year 2026 | $1.24B to $1.25B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Sotera Health filed with the SEC
Sotera Health Delivers Strong Second-Quarter and
Results of operations · EX-99.1 to Form 8-K
Sotera Health Delivers Strong First-Quarter 2026 Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Sotera Health Delivers 20th Consecutive Year
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Sotera Health to Showcase Continued Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Strong Second-Quarter and
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports First-Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results;
Results of operations · EX-99.1 to Form 8-K
Sotera Health Chairman and CEO Presents at
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director
Other events · EX-99.1 to Form 8-K
Sotera Health to Share Next Chapter of Growth at 2024 Investor Day
Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Second-Quarter and First-Half 2024 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Announces Closing of $1.5 Billion Term Loan B and
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sotera Health Reports First-Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K/A
Sotera Health Reports First-Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Fourth-Quarter and Full-Year 2023 Results;
Results of operations · EX-99.1 to Form 8-K
Sotera Health Chairman and CEO Presents at
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports Third-Quarter and Year-to-Date 2023 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Second-Quarter and First-Half 2023 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Announces Jon Lyons as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Finalizes Settlement of Ethylene Oxide Litigation in Illinois
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports First-Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Amends and Upsizes Revolving Credit Facility
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports Fourth-Quarter and Full-Year 2022 Results;
Results of operations · EX-99.1 to Form 8-K
Sotera Health Closes on $500 Million Term Loan B Financing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Confirms Preliminary 2022 Full-Year Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
of Ethylene Oxide Litigation in Illinois
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Chairman and CEO Presents at
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports Third-Quarter and Year-to-Date 2022 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Second-Quarter and First-Half 2022 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Announces Second-Quarter 2022 Earnings Release Date
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sotera Health Reports First-Quarter 2022 Results
Results of operations · EX-99.1 to Form 8-K
Sotera Health Reports Fourth-Quarter and Full-Year 2021 Results;
Results of operations · EX-99.1 to Form 8-K
JP Morgan Healthcare Conference MICHAEL B. PETRAS, JR. CHAIRMAN AND CHIEF EXECUTIVE OFFICER January 11, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Sotera Health Chairman and CEO Presents at
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
JP Morgan Healthcare Conference MICHAEL B. PETRAS, JR. CHAIRMAN AND CHIEF EXECUTIVE OFFICER January 11, 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
January 2022 Governance Engagement Presentation
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Sotera Health Reports Third-Quarter and Year-to-Date 2021 Results
Results of operations · EX-99.1 to Form 8-K